A team comprising researchers from Alcediag, University Hospital of Montpellier, Center for Psychiatry Les Toises in Lausanne and professor David J. Kupffer From University of Pittsburgh A range of blood biomarkers have been identified and validated to me Two-way disorder. These findings, recently published in the leading scientific journal Nature, led to the development of the first Diagnosis the blood a test This disorder affects more than 60 million people worldwide.
MONTPELLIER, France And the ParisAnd the June 9, 2022 /PRNewswire/ — Alcediag, a French precision psychiatry company and a pioneer in biological diagnostics in mental health, announces the publication, in Nature: Translational psychiatryfrom a study that identified a panel of six blood biomarkers, the main distinguishing features of bipolar disorder.
While an estimated 300 million people worldwide suffer from depression, up to 40% of them can actually be affected by bipolar disorder. This chronic disorder is characterized by alternating phases of depression and mania. The stages of depression are similar to so-called unipolar depression, making the diagnosis complex and lengthy. As a result, delays in diagnosis are significant, exceeding 7 years on average. However, the management and treatment of bipolar disorder and depression vary greatly, making timely and reliable diagnosis critical.
For the first time, the study led by Alcediag, including a group of 410 people, provides such an accurate and reliable test able to distinguish between the depressive stages of bipolar disorder and unipolar depression. This test, which has high diagnostic performance and a specificity and sensitivity greater than 80%, is made possible thanks to the combined use of RNA editing and artificial intelligence (AI). The six biomarkers identified identical alterations in the RNA sequence of genes associated with bipolar disorder.
The work presented here continues through a European project called EDIT-B, named after the test, and with the support of EIT Health (European Institute of Innovation and Technology for Health). This project aims for regulatory verification in accordance with European Regulation IVDR 2017/746. Launched in March, this public-private partnership includes Alcediag and center Psychiatry Copenhagen area in Denmark (Prof. L.Kessing), Clinical Hospital in Barcelona And the Foundation of the Clinique Hospital Barcelona Fundació Clinic per la Recerca Biomèdica (Professor e Vita), GHU Paris Psychiatry and Neurosciences (Professor C. Henry), Parc Sanitary Saint Joan de Deu Hospital and Fundació Sant Joan de Déu (Professor JM. Haro), ProductLife Group and Synlab .
“I am happy and proud to see this paper published in Nature Magazine of Translational Psychiatry,” He said Dina WisemanExecutive Vice President of Alcediag. “The significance of our team’s work is to harness the power of RNA editing, a mechanism that regulates RNA stability, splicing, gene expression, and protein synthesis to create a high-performance assay capable of distinguishing between unipolar depression (UD) and bipolar depression (BD), Paving the way for faster and more accurate diagnoses.”
Mr David Kupfer Department of Psychiatry in University of Pittsburgh medical school (United States of America) Add:
“I have mentioned before how important it is for psychiatrists who treat patients to be able to provide an accurate diagnosis as quickly as possible, so that appropriate treatment can begin as quickly as possible. I am honored to be a part of research that makes, for the first time, a high-performance test to accurately diagnose bipolar depression. “
Jean Philip LangeMD, chief medical officer at Les Toises Center for Psychiatry and Psychotherapy and expert advisor to Alcediag: “I am proud of Alcediag’s achievement and the research team in demonstrating clinical evidence that EDIT-B, a high-performance test, is able to differentiate Unipolar from bipolar depression and help clinicians in Psychiatry aims to provide more accurate diagnoses faster for their patients, thereby improving the overall course of care and outcomes for them.”
About the fence:
Alcediag is an innovative diagnostic company focused on mental health, developing a platform that harnesses the latest molecular biology and artificial intelligence to discover and use novel biomarkers based on RNA editing in clinical routine. Alcediag is a subsidiary of Alcen, a diversified French industrial group with a strong focus on innovation and developing societal challenges.
For more information visit: www.alcediag-alcen.com
e: [email protected]
Tel: +33 6 87 62 84 35